Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis

被引：0
|
作者：
Hamid, Omid [1 ]
Weise, Amy [2 ]
Lewis, Karl D. [3 ]
Kim, Tae Min [4 ]
McKean, Meredith [5 ]
Lakhani, Nehal J. [6 ]
Kaczmar, John [7 ]
Papadopoulos, Kyriakos P. [8 ]
Chen, Shuquan [9 ]
Mani, Jayakumar [9 ]
Gullo, Giuseppe [9 ]
机构：
[1] Cedars Sinai Affiliate, Angeles Clin & Res Inst, Los Angeles, CA USA
[2] Henry Ford Hosp, Detroit, MI USA
[3] Univ Colorado, Denver Canc Ctr, Aurora, CO USA
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[6] START Midwest, Grand Rapids, MI USA
[7] Hollings Canc Ctr, Charleston, SC USA
[8] START San Antonio, San Antonio, TX USA
[9] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
43001
引用
收藏
页码：AB207 / AB207
页数：1
相关论文
共 50 条
  • [1] Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
    Hamid, Omid
    Lewis, Karl D.
    Weise, Amy
    McKean, Meredith
    Papadopoulos, Kyriakos P.
    Crown, John
    Kim, Tae Min
    Lee, Dae Ho
    Thomas, Sajeve S.
    Mehnert, Janice
    Kaczmar, John
    Lakhani, Nehal J.
    Kim, Kevin B.
    Middleton, Mark R.
    Rabinowits, Guilherme
    Spira, Alexander I.
    Yushak, Melinda
    Mehmi, Inderjit
    Fang, Fang
    Chen, Shuquan
    Mani, Jayakumar
    Jankovic, Vladimir
    Wang, Fang
    Fiaschi, Nathalie
    Brennan, Laura
    Paccaly, Anne
    Masinde, Sheila
    Salvati, Mark
    Fury, Matthew G.
    Kroog, Glenn
    Lowy, Israel
    Gullo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (24)
  • [2] Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, plus cemiplimab in advanced melanoma
    Hamid, Omid
    Weise, Amy
    Kim, Tae Min
    McKean, Meredith
    Lakhani, Nehal J.
    Kaczmar, John
    Papadopoulos, Kyriakos P.
    Chen, Shuquan
    Mani, Jayakumar
    Jankovic, Vladimir
    Kroog, Glenn
    Sims, Tasha
    Lowy, Israel
    Gullo, Giuseppe
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
  • [3] Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC
    Cho, Byoung Chul
    Dy, Grace K.
    Kim, Tae Min
    Sarker, Debashis
    Hamid, Omid
    Williamson, Stephen K.
    Kim, Sang-We
    Husain, Hatim
    Chen, Shuquan
    Mani, Jayakumar
    Jankovic, Vladimir
    Paccaly, Anne
    Masinde, Sheila
    Lowy, Israel
    Brennan, Laura
    Gullo, Giuseppe
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : S25 - S25
  • [4] Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
    Hamid, O.
    Weise, A.
    Kim, T. M.
    Mckean, M. A.
    Lakhani, N. J.
    Kaczmar, J.
    Papadopoulos, K. P.
    Chen, S.
    Mani, J.
    Jankovic, V.
    Kroog, G.
    Sims, T.
    Lowy, I.
    Gullo, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S905 - S905
  • [5] Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
    Hamid, O.
    Weise, A.
    Kim, T. M.
    Mckean, M.
    Lakhani, N.
    Crown, J.
    Kaczmar, J.
    Papadopoulos, K.
    Chen, S.
    Mani, J.
    Jankovic, V.
    Kroog, G.
    Sims, T.
    Lowy, I.
    Gullo, G.
    ANNALS OF ONCOLOGY, 2022, 33 : S1598 - S1598
  • [6] Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanc
    Cho, Byoung Chul
    Dy, Grace K.
    Kim, Tae Min
    Sarker, Debashis
    Hamid, Omid
    Williamson, Stephen K.
    Kim, Sang -We
    Husain, Hatim
    Fang, Fang
    Chen, Shuquan
    Mani, Jayakumar
    Jankovic, Vladimir
    Paccaly, Anne
    Masinde, Sheila
    Lowy, Israel
    Brennan, Laura
    Salvati, Mark
    Fury, Matthew
    Lewis, Karl
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E8 - E9
  • [7] First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
    Lakhani, Nehal J.
    Papadopoulos, Kyriakos P.
    Johnson, Melissa Lynne
    Park, Haeseong
    Wang, Ding
    Yap, Timothy A.
    Dowlati, Afshin
    Maki, Robert G.
    Ulahannan, Susanna
    Lynce, Filipa
    Kelly, Karen
    Williamson, Stephen
    Malhotra, Jyoti
    Chen, Shuquan
    Gonzalez Ortiz, Ana
    Jankovic, Vladimir
    Paccaly, Anne
    Masinde, Sheila
    Mani, Jayakumar
    Lowy, Israel
    Gullo, Giuseppe
    Sims, Tasha
    Kroog, Glenn
    CLINICAL CANCER RESEARCH, 2024, 30 (24) : 5601 - 5611
  • [8] Defining the signaling mechanisms of Lymphocyte Activation Gene-3 (LAG-3) in T cells
    Alhumeed, N.
    Thaventhiran, T.
    Al-Huseini, L.
    Yeang, H. X. Aw
    Sathish, J.
    IMMUNOLOGY, 2013, 140 : 154 - 154
  • [9] Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
    Atkinson, Victoria
    Khattak, Adnan
    Haydon, Andrew
    Eastgate, Melissa
    Roy, Amitesh
    Prithviraj, Prashanth
    Mueller, Christian
    Brignone, Chrystelle
    Triebel, Frederic
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [10] Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II
    Bruniquel, D
    Borie, N
    Hannier, S
    Triebel, F
    IMMUNOGENETICS, 1998, 48 (02) : 116 - 124
12345